Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Journal of Cardiology

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(02)02329-9PMID 12031731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Extracellular Ionized Calcium in the In Vitro Assessment of GPIIb/IIIa Receptor Antagonists

  2004cited by this paper
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

  2001cited by this paper
• Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition

  2001cited by this paper
• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.

  2001cited by this paper
• Visualization of Discrete Microinfarction After Percutaneous Coronary Intervention Associated With Mild Creatine Kinase-MB Elevation

  2001cited by this paper
• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

  2001cited by this paper
• Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

  2001cited by this paper
• A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

  2001cited by this paper
• Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.

  2001cited by this paper
• Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.

  2001cited by this paper
• Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization

  2001cited by this paper
• Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.

  1999cited by this paper
• Rapid platelet-function assay: an automated and quantitative cartridge-based method.

  1999cited by this paper
• Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

  1999cited by this paper
• The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury.

  1998cited by this paper
• Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.

  1997cited by this paper
• Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

  1996cited by this paper

• Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis

  2023cites this paper
• Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases

  2018cites this paper
• Integrin &agr;IIb&bgr;3: From Discovery to Efficacious Therapeutic Target

  2013cites this paper
• Intra-Arterial Infusion of a Glycoprotein IIb/IIIa Antagonist for the Treatment of Thromboembolism During Coil Embolization of Intracranial Aneurysm: A Comparison of Abciximab and Tirofiban

  2013cites this paper
• Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment

  2012cites this paper
• Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates

  2012cites this paper
• Current issues with glycoprotein IIb-IIIa antagonists.

  2011cites this paper
• Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

  2011cites this paper
• A randomized two‐by‐two comparison of high‐dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TE

  2011cites this paper
• Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.

  2011cites this paper
• Safety evaluation of tirofiban

  2010cites this paper
• eri-Procedural Platelet Function and Platelet nhibition in Percutaneous Coronary Intervention

  2008cites this paper
• Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.

  2008cites this paper
• Angioplastia primária via radial com doses aumentadas de tirofiban: uma técnica segura e efetiva

  2007cites this paper
• Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.

  2006cites this paper
• Platelet activation and progression to complications.

  2006cites this paper
• Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.

  2006cites this paper
• The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.

  2006cites this paper
• Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.

  2006cites this paper
• Assessing Platelet Function in Clinical Trials

  2005influential citation
• Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.

  2005cites this paper
• Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

  2004cites this paper
• Development of glycoprotein IIb–IIIa antagonists: translation of pharmacodynamic effects into clinical benefit

  2004cites this paper
• Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement

  2004cites this paper
• Comparative Pharmacodynamic Evaluation of Eptifibatide and Abciximab in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: The TAM2 Study

  2004cites this paper
• Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.

  2004cites this paper
• Bedside Platelet Monitoring

  2004cites this paper
• Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.

  2003cites this paper
• The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.

  2003cites this paper
• Tirofiban in Interventional Cardiology

  2003cites this paper
• Glycoprotein IIb/IIIa Receptor Antagonists

  2003cites this paper
• Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing

  2003cites this paper
• Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI

  2003cites this paper
• Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention.

  2003cites this paper
• Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part I

  2003cites this paper
• Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention

  2003cites this paper
• Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention.

  2003cites this paper
• Optimizing outcomes in ST-segment elevation myocardial infarction.

  2003cites this paper
• Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.

  2003cites this paper
• Comparative Pharmacology of GP IIb/IIIa Antagonists

  2003cites this paper
• Einfluss der kombinierten antithrombozytären Therapie auf die Plättchenfunktion bei Patienten mit koronarer Herzkrankheit im Rahmen der Implantation koronarer Gefäßstützen

  2003cites this paper
• Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.

  2002cites this paper
• From Discovery to Efficacious Therapeutic Target

  year unknowncites this paper